جست‌وجوی استاد و پژوهشگر

• Genomics
• Cardiovascular Genetics
• Pharmacogenetics
• +۷ مورد دیگر

Dr. Ulrich Broeckel is a Professor and Chief of the Division of Genomic Pediatrics at the Medical College of Wisconsin. He serves as Research Unit Leader for Genetics and Genomics at the Children's Research Institute and maintains membership in three major research centers: the Cancer Center, the Cardiovascular Research Center, and the Mellowes Center for Genomic Sciences and Precision Medicine. His extensive academic contributions span multiple disciplines within genomic medicine. Dr. Broeckel's research focuses on cardiovascular genomics, pharmacogenetics, and structural variant analysis. His work encompasses genome-wide association studies of cardiovascular traits, genetic factors in drug response, and the development of genomic reference materials. He investigates how genetic variation influences blood pressure regulation, coagulation factors, and drug-induced cardiotoxicity, with recent work utilizing hiPSC-derived cardiomyocytes for personalized medicine applications. His methodological expertise includes whole genome sequencing, GWAS, exome analysis, DNA copy number variation analysis, and high-throughput nucleotide sequencing. Analysis of Dr. Broeckel's recent publications (2023-2024) reveals three major thematic areas: 1) Development of pharmacogenomic reference materials (DPYD, CYP2D6, CYP3A4/5), 2) Cardiovascular genomics including polygenic risk scores for blood pressure response, and 3) Application of hiPSC-derived models for studying drug responses. His work consistently emphasizes practical applications of genomic discoveries with strong representation in high-impact collaborative studies through the TOPMed Consortium. Dr. Broeckel's research has significant translational impact, particularly in pharmacogenomics where his work directly informs clinical testing guidelines. His development of reference materials for genetic testing has practical applications in clinical laboratories. The work on polygenic risk scores for blood pressure response and cardiotoxicity prediction has direct implications for personalized medicine approaches in cardiology and oncology. Dr. Broeckel is deeply embedded in major national collaborative research networks, particularly the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. He has contributed to numerous multi-institutional projects including the GeT-RM Collaborative Project focused on pharmacogenetic reference materials. His authorship on papers with dozens of co-authors across multiple institutions demonstrates extensive national and international collaboration in large-scale genomic studies.

• Molecular genetics of prostate cancer
• Fibroblast growth factors
• Benign Prostatic Hyperplasia
• +۳ مورد دیگر

Michael M. Ittmann, M.D., Ph.D. is a Professor and William D. Tigertt Chair in Pathology at Baylor College of Medicine, where he also serves as Co-Leader of the Cancer Biology Program and Director of the Human Tissue Acquisition & Pathology Shared Resource at the Dan L Duncan Comprehensive Cancer Center. His research program focuses on molecular mechanisms of prostate cancer development and progression. Dr. Ittmann's research interests center on molecular genetics of prostate cancer , particularly investigating fibroblast growth factor signaling pathways, DNA methylation changes in prostate cancer, and racial disparities between African American and Caucasian prostate cancer patients. His laboratory has made significant contributions to understanding the role of FGFR signaling in prostate cancer progression and metastasis, as well as the biological significance of the TMPRSS2/ERG gene fusion. Dr. Ittmann's laboratory maintains active research funding from multiple sources including the Department of Defense Prostate Cancer Program and the Department of Veterans Affairs, with current projects focusing on enhancing radiation therapy outcomes, tumor microenvironment biomarkers in African American prostate cancer, and novel oncogenic pathways specific to African American prostate cancer. His leadership roles include serving as Co-Leader of the Cancer Biology Program at the Dan L Duncan Comprehensive Cancer Center and Director of the Human Tissue Acquisition & Pathology Shared Resource, which provides critical infrastructure for prostate cancer research at Baylor College of Medicine.

Andrew J Sharpمشاهده پروفایل

استاد

• Genomics
• Human Genome Research
• Structural Variation
• +۱۴ مورد دیگر

Andrew J Sharp is a Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. He serves as Co-Director of the Graduate Program in Genetics and Genomic Sciences and directs two graduate courses: BSR2400 Translational Genomics and BSR4401 Genetics and Genomics Journal Club. Professor Sharp leads the Sharp lab, an integrated research environment combining experimental and bioinformatic approaches to study the human genome and disease through a 'reverse genetics' strategy. His research focuses on structural variation, epigenetics (particularly DNA methylation), gene expression, and tandem repeat DNA, with applications to understanding mental retardation syndromes, autism, schizophrenia, diabetes, epilepsy, multiple sclerosis, Alzheimer's disease, and neural tube defects. His research has led to significant discoveries, including identifying genetic syndromes accounting for approximately 2% of mental retardation cases worldwide and discovering the most common genetic risk factor for epilepsy. His work has been published in top journals including Nature Genetics and The New England Journal of Medicine . Professor Sharp's publication record shows a strong focus on genomic technologies and their application to human disease, with recent work emphasizing tandem repeat variation, phenome-wide association studies, and epigenetic mechanisms in neurodegenerative disorders. His notable awards include: 2009 Young Investigator Award for Outstanding Science from the European Society of Human Genetics 2006 Trainee Award (postdoctoral) from the American Society of Human Genetics 2002 Trainee Award (predoctoral) from the American Society of Human Genetics Professor Sharp welcomes students interested in human genetics and genomics research, offering a diverse environment for gaining exposure to innovative research areas. His lab provides opportunities for both experimental and computational research in human genome studies, with a focus on translating genomic discoveries into understanding human disease mechanisms.

• Pediatric Oncology
• Neuroblastoma Research
• Cancer Genetics
• +۳ مورد دیگر

Professor Deborah Tweddle is a faculty member at Newcastle University specializing in pediatric oncology, with a primary focus on neuroblastoma and related childhood cancers. Her research spans cancer genetics, clinical pharmacology in neonates and infants, and the application of advanced genomic technologies to improve diagnosis and treatment. Her research interests center on the genetic underpinnings of neuroblastoma (particularly ALK aberrations), tumor evolution, and evidence-based dosing guidelines for chemotherapy in infants. She employs techniques such as optical genome mapping, cell-free DNA analysis, and serial tumor sequencing to investigate tumor heterogeneity and identify therapeutic targets, with emphasis on translating genomic findings into clinical applications. Analysis of her 2021-2025 publications reveals consistent focus on neuroblastoma through large collaborative studies including the UK Children's Cancer and Leukaemia Group (UK CCLG) and European Neuroblastoma Study Group (SIOPEN). Her work bridges laboratory research and clinical trials, addressing critical gaps in pediatric pharmacology, tumor genomics, and risk-stratified treatment approaches. No scientific awards were mentioned in the provided text. Professor Tweddle leads major research consortia including UK CCLG and SIOPEN trials, indicating significant grant funding and leadership in multinational studies. While specific grant details are absent, her role in nationwide clinical trials (e.g., BEACON-Neuroblastoma) demonstrates substantial research infrastructure. No student mentoring information appears in the current publication records. She collaborates extensively across UK and European institutions, frequently co-authoring with Newcastle colleagues like Professor Gareth Veal (clinical pharmacology) and Dr. Shelby Barnett, reflecting a team-based approach to advancing neuroblastoma therapeutics through integrated laboratory-clinical frameworks.

• Social Genomics
• Psychoneuroimmunology
• Inflammation
• +۶ مورد دیگر

Dr. Steven W. Cole is a Professor-in-residence in the Department of Psychiatry and Biobehavioral Sciences at the UCLA David Geffen School of Medicine. His work bridges the fields of social genomics, psychoneuroimmunology, and behavioral medicine, with a particular focus on how social experiences get 'under the skin' to influence health outcomes through molecular pathways. Dr. Cole's research explores the biological mechanisms linking social adversity to health disparities, with particular emphasis on inflammation, stress responses, and gene expression patterns. His work has been instrumental in characterizing the Conserved Transcriptional Response to Adversity (CTRA), a pattern of gene expression associated with social threat and stress that shows increased pro-inflammatory activity and decreased antiviral responses. His research spans multiple populations including cancer survivors, sexual minorities, and individuals experiencing socioeconomic disadvantage. Analysis of Dr. Cole's recent publications (2024-2025) reveals a continued focus on social genomics approaches to understanding health disparities. His work examines how neighborhood disadvantage, discrimination, and social connection influence molecular pathways related to cancer outcomes, aging, and immune function. There's a strong emphasis on translational research that connects basic molecular mechanisms with clinical applications, particularly in oncology and mental health contexts. Dr. Cole's research program involves extensive collaboration across disciplines, working with oncologists, psychologists, geneticists, and public health researchers to examine the molecular underpinnings of social determinants of health. His work has been supported by numerous NIH grants focusing on the biological embedding of social experiences and their health consequences. Dr. Cole leads a research team that integrates molecular biology with social and behavioral science to develop a comprehensive understanding of how our social world shapes our biology. His laboratory employs cutting-edge genomic techniques to analyze how social experiences influence gene expression patterns in immune cells, providing critical insights into the pathways linking social adversity to disease.

• Medical Genetics
• Molecular Diagnostics
• Genetic Disorders
• +۳ مورد دیگر

Hakan GÜRKAN is a Professor at Trakya University's Faculty of Medicine, Department of Medical Genetics. His academic journey includes a Bachelor's degree (1998), Master's (2006), Ph.D. (2011), and post-doctoral studies (2012). He attained the rank of Associate Professor in 2015 and Professor in 2021, both at Trakya University. His research focuses on medical genetics , with emphasis on molecular diagnostics, genetic disorders (e.g., autism, thyroid cancer, cardiomyopathies), and genomic variations. He employs advanced techniques like next-generation sequencing and array CGH to investigate phenotype-genotype relationships in rare diseases. GÜRKAN's publications (2022–2024) reveal a strong focus on neurodevelopmental disorders, oncogenetics, and prenatal diagnostics. His work frequently addresses Turkish population-specific genetic variants and their clinical implications. Awards & Honors: Analysis of THRΒ Gene (2017) BRAFV600E mutation in thyroid cancer (2016) Factor X deficiency genetics (2016) Thrombophilia/recurrent miscarriage panels (2016) HLA-B polymorphism (2015) Toll-like receptor polymorphisms in atopic dermatitis (2015) He leads TÜBİTAK-funded projects (e.g., genetic screening in autism, Lynch syndrome) and serves on ethics committees. As an editorial board member for Balkan Medical Journal , he reviews genetics research. He also supervised a Master's thesis on MTHFR gene methylation in male infertility (2016).

• Medical Genetics
• Neurodevelopmental Disorders
• Epilepsy Genetics
• +۵ مورد دیگر

Sinem YALÇINTEPE is an Associate Professor in the Department of Medical Genetics at Trakya University Faculty of Medicine, where she has been working since 2022. She earned her medical degree from Ege University School of Medicine in 2009 and has established herself as a prominent researcher in medical genetics with a focus on neurodevelopmental disorders, epilepsy genetics, and chromosomal abnormalities. Her research interests span multiple areas of medical genetics, with particular emphasis on neurodevelopmental disorders, epilepsy genetics, chromosomal abnormalities, thrombophilia and pregnancy loss, and next-generation sequencing applications. She has made significant contributions to understanding the genetic basis of various conditions including Desanto-Shinawi Syndrome, Jacobsen Syndrome, and various neurodevelopmental disorders. Her work frequently involves applying advanced genomic techniques to improve diagnostic accuracy and understand genotype-phenotype correlations. Analysis of her recent publications reveals a strong trend toward applying next-generation sequencing technologies to diagnose and understand complex genetic disorders. Her research spans from fundamental genetic mechanisms to clinical applications, with particular focus on neurodevelopmental conditions, epilepsy syndromes, and chromosomal disorders. She has made notable contributions to understanding rare genetic syndromes in the Turkish population and has published extensively on the application of genomic technologies in clinical diagnostics. Dr. YALÇINTEPE actively collaborates with national and international researchers through consortia such as the National Genetics Consortium. Her work demonstrates strong integration between basic research and clinical applications, with numerous publications focusing on translating genetic findings into improved diagnostic approaches and potential therapeutic strategies.

• Nutritional Immunology
• Pharmacology
• Genetics
• +۵ مورد دیگر

Henrik Berg Rasmussen is a Lecturer at the Department of Biomedical Sciences, University of Copenhagen, specializing in Nutritional Immunology. His research spans pharmacology, genetics, and immunology with a particular focus on drug development for viral infections and genetic factors in mental disorders. His research interests primarily center around Nutritional Immunology , Pharmacology of antiviral agents , and Genetic factors in schizophrenia and mental disorders . Dr. Rasmussen has made significant contributions to understanding the pharmacokinetics of nucleoside analogs like GS-441524 and Molnupiravir for COVID-19 treatment, as well as investigating genetic variants related to carboxylesterase 1 and their implications for drug metabolism. His publication trends show a strong focus on interdisciplinary research connecting pharmacology with genetics, particularly in the areas of antiviral therapeutics and psychiatric genetics. Recent work has centered on critical assessment of COVID-19 treatments, while earlier work focused on schizophrenia genetics and enzyme function. Dr. Rasmussen collaborates extensively with researchers across multiple institutions, as evidenced by his co-authorship on large consortium papers including the Schizophrenia Working Group of the Psychiatric Genomics Consortium and the Wellcome Trust Case Control Consortium 2. His laboratory work appears to focus on the intersection of nutritional science and immunology, with particular attention to how genetic variations affect drug metabolism and response, though specific lab details aren't provided in the available information.

• Cytogenetics
• Translocations and inversions
• Next generation sequencing
• +۷ مورد دیگر

Niels Tommerup is a Professor of Medical Genetics at the Department of Cellular and Molecular Medicine, University of Copenhagen, where he has served since 1996. He previously directed the Wilhelm Johannsen Centre for Functional Genome Research (2001-2013) and was Deputy Head of Department (2007-2019). His research group focuses on mapping balanced chromosomal rearrangements (BCR) to identify disease genes, regulatory domains (Topological Associating Domains), and novel genetic mechanisms, as well as characterizing germline chromothripsis and functional studies of non-coding RNA genes. Tommerup earned his DMSc. in genetics (1994) and medical degree (Cand.med., 1978) from the University of Copenhagen. His early career included positions as a junior doctor, research assistant, and senior doctor at the J.F. Kennedy Institute in Denmark (1978-89), and as a Consultant at the Department of Medical Genetics, Ullevål University Hospital in Oslo, Norway (1989-91). He has held visiting scientist positions at institutions in London, Australia, and Norway. His research spans multiple areas including cytogenetics, translocations and inversions, next generation sequencing, Topological Associating Domains, Long Range Position Effects, 3D-genome organization, and long noncoding RNAs. Tommerup coordinates the International Breakpoint Mapping Consortium (2014-present), involving over 100 diagnostic cytogenetic laboratories from more than 50 countries across six continents. His work has established that direct gene truncation may explain approximately 18% of BCR-associated developmental disorders, and that long-range position effects may be at least as frequent a cause as gene truncation. His recent publications reveal trends in understanding sex differential responses to viral infections (particularly focusing on the X-chromosome), linking anatomical variation to genetic variation, and developing methods for visualization of nuclear genome organization. His work bridges basic genomic research with clinical applications in developmental disorders, intellectual disability, autism, epilepsy, and other conditions. Det Classenske Fideicommis Boglegat (1987) Iris Preuss's Mindelegat (1994) First Harold Klinger Memmorial Award Lecture, Atlanta, USA (2006) Tommerup has supervised 27 PhD students and 10 postdocs. His editorial roles include service on the boards of Briefings in Functional Genomics, Clinical Genetics, Computational and Structural Biotechnology Journal, PeerJ, and Australasian Med J. He has organized numerous academic events including the International Summer School in Functional Genomics and the Wilhelm Johannsen Symposium. His international collaborations include the EU-concerted action Mendelian Cytogenetics Network and the International Breakpoint Mapping Consortium. Tommerup leads the Tommerup Group which coordinates the International Breakpoint Mapping Consortium and collaborates with Michael Talkowski's group at Harvard to accumulate the largest collection of sequence-resolved germline balanced chromosomal rearrangements. His laboratory combines DNA-DNA-interaction (Hi-C) studies with short and long read sequencing to improve the dissection of complex chromosomal rearrangements. The group has initiated systematic X-inactivation studies of sequence-resolved X;autosomal translocations and X-inversions, and conducts research on germline chromothripsis and host genetic factors underlying sex differential responses to viral infections.

• Cytogenetics
• Chromosome Aberrations
• Genomic Analysis
• +۳ مورد دیگر

Dr. Peining Li is a Professor of Genetics at Yale School of Medicine, where she serves as Director of the Cytogenetics Laboratory and Co-Director of the Fellowship in Laboratory Genetics and Genomics. Her primary affiliations include the Department of Genetics, Yale Center for Genomic Health, and Yale Ventures. She leads a research program focused on structural and functional characterization of human chromosome abnormalities using advanced molecular techniques. Her research interests span: Cytogenetics and chromosome aberration analysis Genomic diagnostics using microarray and sequencing technologies Cancer genomics with focus on hepatocellular carcinoma Reproductive genetics including pregnancy loss mechanisms Recent publications demonstrate her work in pediatric genetic diagnostics, NGS concordance studies, stem cell applications, and ring chromosome characterization. Her lab provides clinical services for diverse specimen types including blood, amniotic fluid, and tumor samples.

• Genetics
• Genomics
• DNA Sequence Analysis
• +۲ مورد دیگر

Dr. Shrikant Mane is a Professor of Genetics at Yale School of Medicine, where he directs the Yale Center for Genome Analysis (YCGA) Shared Resource and The Keck Biotechnology Resource Laboratory. He has over 25 years of research experience in both academic and private industry settings, with expertise in genomic and proteomic analyses using microarray and high-throughput DNA sequencing technologies. Dr. Mane received his Ph.D. in Cancer Biology in 1985 and completed his postdoctoral training at Johns Hopkins University School of Medicine. He has published over 125 scientific articles and holds 2 patents. His research spans genetics, genomics, DNA sequence analysis, neuroscience, and cancer biology, with a particular focus on Mendelian genomics and disease gene discovery. His laboratory work has provided over 58,000 sequence analyses to 225 Yale and 124 non-Yale principal investigators from 72 national and 16 international institutions. Dr. Mane is one of four Principal Investigators of the Yale Center for Mendelian Genomics, established in 2012 through an $11.2 million grant from NHGRI. His recent publications (2023-2025) demonstrate a strong focus on identifying genetic causes of kidney disorders, congenital heart disease, and neurodevelopmental conditions through large-scale genomic studies published in high-impact journals including Nature, Nature Communications, and PNAS. Notable Achievements: Principal Investigator of the Yale Center for Mendelian Genomics ($11.2 million NHGRI grant) Director of Yale Center for Genome Analysis serving hundreds of researchers worldwide Published over 125 scientific articles in genetics and genomics Extensive experience with genomic technologies spanning 25+ years Dr. Mane's laboratory serves as a major resource for genomic analysis at Yale and beyond, supporting numerous research projects through cutting-edge sequencing and analysis capabilities. His research program bridges technological development with clinical applications, particularly in the area of Mendelian disease gene discovery.

Joseph Buxbaumمشاهده پروفایل

استاد

• Autism Spectrum Disorder
• Alzheimer's Disease
• Schizophrenia
• +۷ مورد دیگر

Joseph Buxbaum serves as Professor of Psychiatry at Icahn School of Medicine at Mount Sinai and Director of the Seaver Autism Center for Research and Treatment. His academic appointments span multiple institutes including the Friedman Brain Institute, Genetics and Genomic Sciences, and the Mindich Child Health and Development Institute, reflecting his interdisciplinary research approach. Dr. Buxbaum's research focuses on the genetic and molecular mechanisms underlying neurodevelopmental and psychiatric disorders. His laboratory investigates autism spectrum disorder through genetic mapping and functional characterization of susceptibility genes like SHANK2 and AGC1. In schizophrenia research, his team pioneered the oligodendrocyte dysfunction hypothesis based on microarray studies. For Alzheimer's disease, they examine amyloid precursor protein signaling pathways and calsenin function in amyloid processing. His publication record demonstrates sustained productivity with 493 research outputs including over 400 articles. Recent work shows continued high output with 16 publications in 2023 and multiple 2024-2025 publications in high-impact journals. Analysis of his recent articles reveals strong emphasis on genomic approaches to autism, OCD, and dementia, with particular focus on rare variants, cross-disorder analyses, and functional validation. Dr. Buxbaum's scientific impact is evidenced by his h-index of 132 and 85,766 citations. While specific awards aren't listed in the source material, his leadership of the Seaver Autism Center and participation in major genomic consortia indicate significant recognition in the field. As director of the Laboratory of Molecular Neuropsychiatry, he mentors trainees in molecular analysis of neurological diseases using state-of-the-art techniques. His lab maintains active collaborations through the Trans-Ancestry OCD Genomics Initiative, Alzheimer's Disease Genetics Consortium, and international autism research networks. Current research leverages genomic sequencing, animal models, and stem cell technologies to advance understanding of neurodevelopmental disorders.

Dalila C Pintoمشاهده پروفایل

دانشیار

• Neuropsychiatric Disorders
• Genomics
• Transcriptomics
• +۵ مورد دیگر

Dalila C Pinto, PhD, is an Associate Professor at Icahn School of Medicine at Mount Sinai, with joint appointments in Psychiatry and Genetics and Genomic Sciences. She holds affiliations with the Seaver Autism Center, Mindich Child Health Institute, Friedman Brain Institute, Icahn Genomics Institute, and the PsychENCODE Consortium. Her research integrates genomics, transcriptomics, and bioinformatics to study neuropsychiatric disorders. Key focus areas include: Genetic architecture of autism, epilepsy, and schizophrenia Brain-specific gene regulation and proteomics De novo mutations and rare variants in neurodevelopmental disorders Computational frameworks for multi-omics data analysis Recent publication trends (2020-2024) highlight her work on brain proteomics in psychiatric disorders, epilepsy genetics, stem cell transcriptomics, and schizophrenia risk loci. Her team consistently contributes to large consortia like PsychENCODE and Epi25, emphasizing translational genomics. Dr. Pinto leads the Pinto Lab, which develops innovative genomic approaches to map disease mechanisms. The lab is based in the Hess Center for Science & Medicine and collaborates internationally to advance neuropsychiatric research.

Paula Maria Vieira Jorgeمشاهده پروفایل

استادیار

• Clinical Genetics
• Genomics
• Molecular Biology
• +۶ مورد دیگر

Paula Maria Vieira Jorge is an Assistant Professor of Genetics and Genomics at the Abel Salazar Institute of Biomedical Sciences (ICBAS) of the University of Porto, where she teaches and trains future genetics professionals. She holds dual institutional roles as both a university faculty member at ICBAS-UP and a Clinical Laboratory Geneticist at Centro de Genética Médica Jacinto de Magalhães, CHUPorto. Her research interests span Clinical Genetics, Genomics, and Molecular Biology with specific focus on neurodevelopmental disorders, female fertility genetics, and X-linked diseases. She leads the Human Clinical and Experimental Genomics (CEHG) research group at UMIB and directs the Cytogenetics Laboratory, where she preserves Professor Beatriz Porto's legacy in Fanconi anemia diagnosis. Dr. Jorge's recent publications demonstrate expertise in copy number variant interpretation, X-chromosome related disorders, and fertility genetics. Her work shows strong translational focus, with several research outcomes directly impacting clinical practice, including patented assessment tools and gene therapy applications. She has received recognition as a Clinical Laboratory Geneticist by the European Board of Medical Genetics and has made significant contributions to the field through publications in high-impact journals like PNAS and the inclusion of new diseases in the OMIM database. Dr. Jorge actively mentors young scientists and collaborates internationally through EUGLOH, EMQN, and COST Actions. She serves in leadership roles including Coordinator of the Scientific Council of the Portuguese Society of Human Genetics and Member of the Scientific Committee for the Doctoral Program in Forensic Sciences at ICBAS-UP.

Erin E Crottyمشاهده پروفایل

استادیار

• Pediatric Neuro-oncology
• Brain Tumor Immunotherapy
• CAR T-cell Therapy
• +۷ مورد دیگر

Dr. Erin E Crotty is an attending physician and pediatric oncologist specializing in brain and spinal cord tumors at Seattle Children's Hospital, where she serves as the clinical oncology lead for the Retinoblastoma Program. She holds an academic appointment as Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine and is affiliated with the Ben Towne Center for Childhood Cancer and Blood Disorders Research. Her educational background includes an MD from George Washington University School of Medicine & Health Sciences, pediatric residency training at Children's National Medical Center in Washington, D.C., and hematology/oncology fellowship at Seattle Children's Hospital/University of Washington with additional translational research training at Fred Hutch Cancer Research Center. Dr. Crotty's research focuses on bringing innovative therapies to children with difficult-to-treat central nervous system tumors, with particular emphasis on immunotherapies, CAR T-cell approaches, and precision medicine. She leads early phase clinical trials for children with brain tumors and serves as site Principal Investigator for the Pacific Pediatric Neuro-oncology Consortium (PNOC) and the Collaborative Network for Neuro-oncology Clinical Trials (CONNECT). Her clinical work includes moderating Seattle Children's weekly Brain Tumor Board for multidisciplinary case reviews. Analysis of Dr. Crotty's recent publications reveals a strong focus on novel therapeutic approaches for pediatric CNS tumors, particularly CAR T-cell therapies targeting multiple antigens (B7-H3, EGFR, HER2, IL-13Ralpha2), liquid biopsy techniques using CSF for disease monitoring, and molecularly guided treatment strategies for high-grade gliomas and medulloblastoma. Her work bridges translational research with clinical application, emphasizing targeted therapies and immunotherapeutic approaches. Dr. Crotty actively contributes to advancing the field through numerous clinical trials including PNOC022 for diffuse midline gliomas, PNOC028 for natural killer cell therapy, and SC-9017 for pediatric low-grade glioma. Her leadership in the Brain Tumor Program at Seattle Children's demonstrates commitment to bringing laboratory discoveries directly to patient care.